Japanese Foundation for Cancer Research

14/20

14To understand the cell of origin in cancer and the molecular mechanism of multi-step carcinogenic processes, we focus on oncogenic transcription factors in hematological and mesenchymal malignancies. We use the genetically engineered and/or ex vivo mouse models in order to identify novel disease genes and pathological genetic pathways that lead cells to cancer.We aim to develop artificial protein-based biomaterials for drug delivery systems and diagnostic devices. To achieve this, we use our proprietary technology named MolCraft, which is a novel type of in vitro protein evolution system based on a hierarchical approach.To establish personalized medicine, we conduct a comprehensive study of cancer genomics using next generation sequencers, microarray, or mass spectrograph in collaboration with the Genome Center. Our goal is to examine cancer genomics, and to develop a prediction system of drug effectiveness and side-effects and bioinformatics methods for drug discovery.Robustness is a system-level property that enables an organism to maintain its functions under any internal and external perturbations. Robust systems also inevitably entail extreme fragility against unexpected perturbation. Our research focuses on understanding robustness trade-offs at the cellular level using yeast, and investigating how to systematically design a “System Drug.�? To establish novel conceptual bases for cancer diagnosis and treatment, we have developed a histomolecular pathological approach to explore solid cancers for novel fusion genes. We have identied 16 fusion kinases including ALK, ROS1, and RET fusions, leading to development of novel therapeutics using specific kinase inhibitors.●Division of Protein Engineering●Division of Cancer Genomics ●Division of Cancer Systems Biology●Pathology Project for Molecular Targets●Division of Carcinogenesis

※こ�?�ペ�?�ジを正しく表示するにはFlashPlayer10.2以上が�?要で�?